Medical Advocates
HIV Infection/Disease
  Lipodystrophy Syndrome

 General Reports
Treatment
ARV/HAART
Hypercholesterolemia
Hyperlipidemia
Hypertriglyceridemia
Insulin Resistance
Quality of Life


 
HIV Metabolic Main HIV Main Page Main New/Newsworthy Home Page  
Last Update: May 11, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       
     Books
 
  FULL-TEXT BOOK CHAPTER
Lipodystrophy Syndrome
Behrens B
HIV Medicine-2003 Hoffmann C, Kamps, BS (editors) Amedeo Group 2003
On-Line Book

          Journal Papers, Abstracts, and Commentaries

 
HIV lipodystrophy syndrome.
Valente AM, Reis AF, Machado DM,
Arq Bras Endocrinol Metabol. 2005 Dec;49(6):871-81.
 Abstract
 
Redefining lipodystrophy syndrome: risks and impact on clinical decision making.
Lichtenstein KA.
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):395-400.
 Abstract
 
Current perspectives on HIV-associated lipodystrophy syndrome.
 Milinkovic A, Martinez E. 
J Antimicrob Chemother. 2005 May 19;
 Abstract

Agreement Analysis of Variables Involved in Lipodystrophy Syndrome Definition in HIV-
Infected Patients.
Belloso WH, Quiros RE, Ivalo SA, et al.
J Acquir Immune Defic Syndr 2003 Jan 1;32(1):104-11
 Abstract

Lipodystrophy Syndrome and Self-Assessment of Well-Being and Physical Appearance in
HIV-Positive Patients.
Oette M, Juretzko P, Kroidl A, et al.
AIDS Patient Care STDS 2002 Sep;16(9):413-7
 Abstract

Metabolic basis of HIV-lipodystrophy syndrome.
Sekhar RV, Jahoor F, White AC, et al.
Am J Physiol Endocrinol Metab 2002Aug;283(2):E332-7
 Abstract

Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of
patients after 3 years of antiretroviral treatment.
Mauss S, Corzillius M, Wolf E, S
HIV Med 2002 Jan;3(1):49-55
Abstract

  
 


Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated
patients with human immunodeficiency virus infection.
Graber AL.
Endocr Pract 2001 Nov-Dec;7(6):430-7
Abstract

Insulin resistance in the HIV-lipodystrophy syndrome.
Grinspoon S.
Trends Endocrinol Metab 2001Nov 1;12(9):413-9
 Abstract

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV
nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy
syndrome.
Carr A, Miller J, Law M, Cooper DA.
AIDS 2000 Feb 18;14(3):F25-32
 Abstract

  

        Conference Reports, Abstracts, and Posters

  CONFERENCE PDF POSTER
 Adipocytokine Levels in the Lipodystrophy Syndrome of HIV-infected Patients
W L Dinges, D Chen, I Shimomura,  et al
(9 CROI)
 PDF Poster   Abstract 		 
Treatment
       
          Journal Papers, Abstracts, and Commentaries
 
Improvement in Highly Active Antiretroviral Therapy-Induced Metabolic Syndrome
by Treatment with Pioglitazone but Not with Fenofibrate: A 2 x 2 Factorial, Randomized,
Double-Blinded, Placebo-Controlled Trial.
 Gavrila A, Hsu W, Tsiodras S et al 
Clin Infect Dis. 2005 Mar 1;40(5):745-9.
Abstract		  
ARV/HAART
       

       Journal Papers, Abstracts, and Commentaries

 
Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients:
considerations for psychosocial aspects.
Fernandes AP, Sanches RS, Mill J, et al
 Rev Lat Am Enfermagem. 2007 Oct;15(5):1041-1045.
Abstract

Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in
aetiopathogenesis.
Nolan D, John M, Mallal S.
Antivir Ther 2001 Sep;6(3):145-60
Abstract
 

  

           Conference Reports, Abstracts, and Posters

  Cumulative nucleoside exposure as a prognostic marker for development of HIV-
associated lipodystrophy syndrome
WF Pewen, BC Calhoun, SA Riddler, et al,
 (15IAC)
 Abstract
 
Lipodystrophy syndrome in HIV infected patients taking a NRTI combination, partial
reversion with a one-week on/off treatment, Oxygen assay, results at 48 weeks
G Hittinger, C Poggi, J M Beyssac, et al
 (15IAC)
 Abstract
 
Outcomes of switching from PI-containing regimens to PI-sparing regimens due to
lipodystrophy
MP Lee, GWB Ng, RWY Chung, et al
 (15IAC)
 Abstract
Hypertriglyceridemia
       
          Journal Papers, Abstracts, and Commentaries
 
Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir
-containing regimen:
an index of atherogenicity?
Badiou S, Merle De Boever C, et al.
Atherosclerosis 2003 May;168(1):107-13
 Abstract		  

           Conference Reports, Abstracts, and Posters

 
Treatment of Hypertriglyceridemia in HIV-infected Patients under HAART, by
(n-3)PolyunsaturatedFatty Acids: A Double-blind Randomized Prospective Trial
in 122 Patients
P De Truchis, M Kirstetter, A Perier, et al
 (12 CROI)
 Abstract

A Randomized, Open-label Clinical Trial of Omega-3-Fatty Acid (Fish Oil)
Supplementation along with Diet and Exercise in HIV-infected Patients with
Hypertriglyceridemia
 DA Wohl, C Cunningham, H-C Tien, et al
 (11 CROI)
 Abstract

Peripheral Lipodystrophy
       
Quality of Life
       

       Journal Papers, Abstracts, and Commentaries

 
Health related quality of life and lipodystrophy syndrome among HIV-infected patients.
Preau M, Bouhnik AD, Spire B, et al 
Encephale. 2006 Oct;32(5 Pt 1):713-9
 Abstract

A qualitative study of the psychosocial implications of lipodystrophy syndrome on
HIV positive individuals.
Power R, Tate HL, McGill SM, Taylor C.
 Sex Transm Infect 2003 Apr;79(2):137-141
 Abstract

Lipodystrophy Syndrome and Self-Assessment of Well-Being and Physical
Appearance in HIV-Positive Patients.
Oette M, Juretzko P, Kroidl A, et al.
AIDS Patient Care STDS 2002 Sep;16(9):413-7
 Abstract

 

           Conference Reports, Abstracts, and Posters

  Quality of life and related psychological factors in HIV-infected patients with
Lipodystrophy Syndrome
A Marin, J L Casado, J Moya, et al
 (15IAC)
 Abstract
 
  Depression as consequence of the lipodystrophy syndrome in HIV-infected patients
A Marin, J L Casado, J Moya, 3et al
 (15IAC)
 Abstract

HIV Metabolic Main HIV Main Page Main New/Newsworthy Home Page  

HIV-Associated Lipodystrophy Syndrome